86 related articles for article (PubMed ID: 15837872)
1. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
Wolf IH; Cerroni L; Kodama K; Kerl H
Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
[TBL] [Abstract][Full Text] [Related]
2. Interventions for melanoma in situ, including lentigo maligna.
Tzellos T; Kyrgidis A; Mocellin S; Chan AW; Pilati P; Apalla Z
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010308. PubMed ID: 25526608
[TBL] [Abstract][Full Text] [Related]
3. Retrospective review of patients with lentigo maligna treated with topical imiquimod 5% (Aldara®) at a single tertiary UK centre: need for more practical standardised treatment guidelines in the UK.
Afzal UM; Ghadiri SJ; Sambi P; Muinonen-Martin A; Mitra A
Clin Exp Dermatol; 2024 Jan; 49(2):163-165. PubMed ID: 37758510
[No Abstract] [Full Text] [Related]
4. Delphi Consensus Among International Experts on the Diagnosis, Management, and Surveillance for Lentigo Maligna.
Longo C; Navarrete-Dechent C; Tschandl P; Apalla Z; Argenziano G; Braun RP; Bataille V; Cabo H; Hoffmann-Wellhenhof R; Forsea AM; Garbe C; Guitera P; Raimond K; Marghoob AA; Malvehy J; Del Marmol V; Moreno D; Nehal KS; Nagore E; Paoli J; Pellacani G; Peris K; Puig S; Soyer HP; Swetter S; Stratigos A; Stolz W; Thomas L; Tiodorovic D; Zalaudek I; Kittler H; Lallas A
Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37403983
[TBL] [Abstract][Full Text] [Related]
5. Observational study of topical imiquimod immunotherapy in the treatment of difficult lentigo maligna.
Craythorne EE; Lawrence CM
Clin Med Oncol; 2008; 2():551-4. PubMed ID: 21892331
[No Abstract] [Full Text] [Related]
6. Lentigo maligna : prognosis and treatment options.
Stevenson O; Ahmed I
Am J Clin Dermatol; 2005; 6(3):151-64. PubMed ID: 15943492
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients.
Ly L; Kelly JW; O'Keefe R; Sutton T; Dowling JP; Swain S; Byrne M; Curr N; Wolfe R; Chamberlain A; Haskett M
Arch Dermatol; 2011 Oct; 147(10):1191-5. PubMed ID: 22006136
[TBL] [Abstract][Full Text] [Related]
8. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature.
Ellis LZ; Cohen JL; High W; Stewart L
Dermatol Surg; 2012 Jun; 38(6):937-46. PubMed ID: 22338583
[TBL] [Abstract][Full Text] [Related]
9. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports.
Spenny ML; Walford J; Werchniak AE; Beltrani V; Brennick JB; Storm CA; Perry AE; Chapman MS
Cutis; 2007 Feb; 79(2):149-52. PubMed ID: 17388218
[TBL] [Abstract][Full Text] [Related]
10. Key points in dermoscopic differentiation between lentigo maligna and solar lentigo.
Tanaka M; Sawada M; Kobayashi K
J Dermatol; 2011 Jan; 38(1):53-8. PubMed ID: 21175756
[TBL] [Abstract][Full Text] [Related]
11. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
13. Topical and Intralesional Immunotherapy for Melanoma In Situ: A Review.
Martínez-Fernández S; González-Sixto B; Espasandín-Arias M; Soto-García D; Flórez Á
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760438
[TBL] [Abstract][Full Text] [Related]
14. Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature.
Vaienti S; Calzari P; Nazzaro G
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2187-2215. PubMed ID: 37615838
[TBL] [Abstract][Full Text] [Related]
15. Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment.
Tambunlertchai S; Geary SM; Salem AK
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297510
[TBL] [Abstract][Full Text] [Related]
16. Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment.
Szeto MD; Maghfour J; Sivesind TE; Anderson J; Olayinka JT; Mamo A; Runion TM; Dellavalle RP
Dermatology; 2021; 237(6):847-856. PubMed ID: 34511591
[TBL] [Abstract][Full Text] [Related]
17. Reviewing Challenges in the Diagnosis and Treatment of Lentigo Maligna and Lentigo-Maligna Melanoma.
Juhász ML; Marmur ES
Rare Cancers Ther; 2015; 3(1):133-145. PubMed ID: 27182482
[TBL] [Abstract][Full Text] [Related]
18. Melanoma in Situ Treated with Topical Imiquimod for Management of Persistently Positive Margins: A Review of Treatment Methods.
Fan Q; Cohen S; John B; Riker AI
Ochsner J; 2015; 15(4):443-7. PubMed ID: 26730231
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
